{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:10:00Z","timestamp":1794712200581,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-025-00789-2","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T02:45:37Z","timestamp":1770086737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative efficacy and safety of IL-17 and IL-23 inhibitors for moderate-to-severe psoriasis in Asian populations: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7719-1545","authenticated-orcid":false,"given":"Mohammad","family":"Alzghool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Jiquan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9678-0512","authenticated-orcid":false,"given":"Musa Bin","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"10281","key":"789_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6.","journal-title":"Lancet"},{"issue":"4","key":"789_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai T-F, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1314258.","journal-title":"N Engl J Med"},{"key":"789_CR3","doi-asserted-by":"publisher","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(15)60125-8. UNCOVER-2 and UNCOVER-3 investigators.","DOI":"10.1016\/S0140-6736(15)60125-8"},{"issue":"3","key":"789_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy and safety of guselkumab, an anti\u2013interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"789_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/1346-8138.17038","volume":"51","author":"Y Tada","year":"2024","unstructured":"Tada Y, Komine M, Okubo Y, Habiro K, Tsuritani K, Morita A. Treatment patterns of systemic drug use in Japanese patients with plaque psoriasis: A retrospective chart review. J Dermatol. 2024;51(2):210\u201322. https:\/\/doi.org\/10.1111\/1346-8138.17038. Epub 2023 Nov 30. PMID: 38031882; PMCID: PMC11484147.","journal-title":"J Dermatol"},{"issue":"2","key":"789_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4103\/ds.DS-D-23-00247","volume":"42","author":"Zhenli Kwan","year":"2024","unstructured":"Kwan Zhenli, Voo Sook Yee Michelle, Tan Wooi Chiang, Tang Jyh Jong, Tang Min Moon, Abdullah Wan Noor Hasbee Wan, et al. Effectiveness of biologic treatment for psoriasis in Malaysia: real-world evidence and review of current evidence from Southeast Asia. Dermatol Sin. 2024;42(2):136\u201345. https:\/\/doi.org\/10.4103\/ds.DS-D-23-00247.","journal-title":"Dermatol Sin"},{"issue":"5","key":"789_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5114\/reum.2022.120752","volume":"60","author":"W Owczarek","year":"2022","unstructured":"Owczarek W. The role of HLA-Cw6 in psoriasis and psoriatic arthritis. Reumatologia. 2022;60(5):303\u20135. https:\/\/doi.org\/10.5114\/reum.2022.120752.","journal-title":"Reumatologia"},{"key":"789_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07130-w","volume":"23","author":"Y Xu","year":"2025","unstructured":"Xu Y, Peng C, Tang S, Zhang L, Liu Y, Huang W, et al. Association of BMI, BMR, BSA, and body weight with psoriasis severity and treatment response: evidence from a real-world cohort. J Transl Med. 2025;23:1129. https:\/\/doi.org\/10.1186\/s12967-025-07130-w.","journal-title":"J Transl Med"},{"key":"789_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s12276-025-01427-y","volume":"57","author":"J Cha","year":"2025","unstructured":"Cha J, Kim TG, Ryu JH. Conversation between skin microbiota and the host: from early life to adulthood. Exp Mol Med. 2025;57:703\u201313. https:\/\/doi.org\/10.1038\/s12276-025-01427-y.","journal-title":"Exp Mol Med"},{"issue":"10272","key":"789_CR10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(21)00486-0","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Langley RG, Gottlieb AB. Efficacy and safety of Bimekizumab in the treatment of moderate-to-severe psoriasis: a randomized trial. Lancet. 2021;397(10272):1517\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(21)00486-0.","journal-title":"Lancet"},{"issue":"4","key":"789_CR11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bjd.19314","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Paul C, van de Kerkhof P, Warren RB, Gottlieb AB, Langley RG, et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. Br J Dermatol. 2021;184(4):640\u201351. https:\/\/doi.org\/10.1111\/bjd.19314.","journal-title":"Br J Dermatol"},{"issue":"1","key":"789_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaad.2022.09.018","volume":"88","author":"RG Langley","year":"2023","unstructured":"Langley RG, Ellis CN, Lebwohl M. Secukinumab versus placebo for moderate-to-severe psoriasis. J Am Acad Dermatol. 2023;88(1):45\u201356. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.018.","journal-title":"J Am Acad Dermatol"},{"issue":"10202","key":"789_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0140-6736(19)31169-1","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Papp KA, Strober BE. Risankizumab versus adalimumab in moderate-to-severe psoriasis: a phase 3 trial. Lancet. 2019;394(10202):423\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(19)31169-1.","journal-title":"Lancet"},{"issue":"2","key":"789_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/1346-8138.16123","volume":"51","author":"Y Cai","year":"2024","unstructured":"Cai Y, Zhang F, Wang W. Efficacy and safety of xeligekimab in the treatment of moderate-to-severe psoriasis: a randomized trial. J Dermatol. 2024;51(2):182\u201390. https:\/\/doi.org\/10.1111\/1346-8138.16123.","journal-title":"J Dermatol"},{"issue":"1","key":"789_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2024.09.031","volume":"92","author":"K Yan","year":"2025","unstructured":"Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, et al. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2025;92(1):92\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.031.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"789_CR16","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/1346-8138.17446","volume":"51","author":"SW Youn","year":"2024","unstructured":"Youn SW, Jo SJ, Park CJ, Kim DH, Shin BS, Jeong KH, et al. Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: a phase 3, randomized, placebo-controlled, double-blinded study. J Dermatol. 2024;51(12):1392\u2013403. https:\/\/doi.org\/10.1111\/1346-8138.17446.","journal-title":"J Dermatol"},{"issue":"10","key":"789_CR17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1097\/CM9.0000000000002873","volume":"137","author":"Y Chen","year":"2024","unstructured":"Chen Y, Geng S, Yang B, Deng Y, Li F, Kang X, et al. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: a 12-week randomized placebo-controlled phase III trial with long-term extension. Chin Med J. 2024;137(10):1190\u20138. https:\/\/doi.org\/10.1097\/CM9.0000000000002873.","journal-title":"Chin Med J"},{"key":"789_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/1346-8138.16667","volume":"50","author":"K Yamanaka","year":"2023","unstructured":"Yamanaka K, Okubo Y, Yasuda I, Saito N, Messina I, Morita A. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: primary analysis and 180-week follow-up results from the phase 3, multicenter immspire study. J Dermatol. 2023;50:195\u2013202. https:\/\/doi.org\/10.1111\/1346-8138.16667.","journal-title":"J Dermatol"},{"key":"789_CR19","doi-asserted-by":"publisher","first-page":"109248","DOI":"10.1016\/j.intimp.2022.109248","volume":"112","author":"X Yu","year":"2022","unstructured":"Yu X, Zhang H, Wang Y, et al. A randomized, double-blind phase III study to demonstrate the clinical similarity of SCT630 to reference adalimumab in Chinese patients with moderate-to-severe plaque psoriasis. Int Immunopharmacol. 2022;112:109248. https:\/\/doi.org\/10.1016\/j.intimp.2022.109248.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"789_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/13543784.2023.2230122","volume":"32","author":"J He","year":"2023","unstructured":"He J, Du W, Yang H, Wang J, Cai C, Ma Q, et al. Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study. Expert Opin Investig Drugs. 2023;32(7):669\u201375. https:\/\/doi.org\/10.1080\/13543784.2023.2230122.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"789_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamadermatol.2024.5059","volume":"161","author":"X Li","year":"2025","unstructured":"Li X, Li B, Yang D, Wang M, Li Q, Wang N, et al. Safety and efficacy of anti-IL-23 monoclonal antibody QX004N for patients with psoriasis: a randomized clinical trial. JAMA Dermatol. 2025;161(3):247\u201355. https:\/\/doi.org\/10.1001\/jamadermatol.2024.5059.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"789_CR22","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1007\/s12325-023-02575-1","volume":"40","author":"M Zheng","year":"2023","unstructured":"Zheng M, Chen X, Wang F, Chen J, Jackson K, Yang F, et al. Pharmacokinetics, safety, and efficacy of Ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: a phase 1, single- and multiple-dose study. Adv Ther. 2023;40(9):3804\u201316. https:\/\/doi.org\/10.1007\/s12325-023-02575-1. (Epub 2023 Jun 25. PMID: 37356077).","journal-title":"Adv Ther"},{"issue":"6","key":"789_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/1346-8138.15763","volume":"48","author":"S Imafuku","year":"2021","unstructured":"Imafuku S, Nakagawa H, Igarashi A, Morita A, Okubo Y, Sano S, et al. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 5-year extension of a phase 3 study (reSURFACE 1). J Dermatol. 2021;48(6):844\u201352. https:\/\/doi.org\/10.1111\/1346-8138.15763.","journal-title":"J Dermatol"},{"issue":"2","key":"789_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/1346-8138.14761","volume":"46","author":"Y Okubo","year":"2019","unstructured":"Okubo Y, Ohtsuki M, Morita A, Yamaguchi M, Shima T, Tani Y, et al. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study. J Dermatol. 2019;46(2):186\u201392. https:\/\/doi.org\/10.1111\/1346-8138.14761.","journal-title":"J Dermatol"},{"key":"789_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00403-019-02024-6","volume":"312","author":"LF Liu","year":"2020","unstructured":"Liu LF, Chen JS, Gu J, et al. Etanercept biosimilar (recombinant human tumor necrosis factor-\u03b1 receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial. Arch Dermatol Res. 2020;312:437\u201345. https:\/\/doi.org\/10.1007\/s00403-019-02024-6.","journal-title":"Arch Dermatol Res"},{"key":"789_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00403-025-04174-2","volume":"317","author":"W Jiang","year":"2025","unstructured":"Jiang W, Li Q, Zheng W. The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis. Arch Dermatol Res. 2025;317:643. https:\/\/doi.org\/10.1007\/s00403-025-04174-2.","journal-title":"Arch Dermatol Res"},{"key":"789_CR27","doi-asserted-by":"publisher","first-page":"adv41105","DOI":"10.2340\/actadv.v105.41105","volume":"105","author":"L Cai","year":"2025","unstructured":"Cai L, Liu H, Mu Z, Tao X, Zhang L, Zhang C, et al. Safety, pharmacokinetics, and efficiency of JS005, a novel anti-interleukin-17A monoclonal antibody, in healthy Chinese adults and patients with moderate to severe psoriasis. Acta Derm Venereol. 2025;105:adv41105. https:\/\/doi.org\/10.2340\/actadv.v105.41105. (PMID: 40135354; PMCID: PMC11977408).","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"789_CR28","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/1346-8138.15789","volume":"48","author":"A Igarashi","year":"2021","unstructured":"Igarashi A, Imafuku S, Okubo Y, et al. Efficacy and safety of Tildrakizumab in Japanese patients with moderate-to-severe plaque psoriasis: results from a 64-week phase 3 study (reSURFACE 1). J Dermatol. 2021;48(7):1064\u201373. https:\/\/doi.org\/10.1111\/1346-8138.15789.","journal-title":"J Dermatol"},{"issue":"8","key":"789_CR29","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial. J Dermatol. 2019;46(8):686\u201394. https:\/\/doi.org\/10.1111\/1346-8138.14941.","journal-title":"J Dermatol"},{"issue":"8","key":"789_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/1346-8138.15733","volume":"48","author":"SJ Seo","year":"2021","unstructured":"Seo SJ, Shin BS, Lee JH, Jeong HE. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: a randomized, phase III, double-blind, placebo-controlled study. J Dermatol. 2021;48(8):807\u201317. https:\/\/doi.org\/10.1111\/1346-8138.15733.","journal-title":"J Dermatol"},{"issue":"12","key":"789_CR31","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","volume":"156","author":"M Augustin","year":"2020","unstructured":"Augustin M, Lambert JL, Zema C, Thompson EHZ, Yang M, Wu EQ, et al. Effect of Risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol. 2020;156(12):1344\u201353. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3617.","journal-title":"JAMA Dermatol"},{"issue":"10201","key":"789_CR32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Foley P, Gordon KB, Langley RG, Papp KA, Wasfi Y, Shen YK. Guselkumab versus Secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(19)31773-8.","journal-title":"Lancet"},{"issue":"1","key":"789_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2436607","volume":"35","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Narbutt J, Girolomoni G, Brzezicki J, Reznichenko N, Zegad\u0142o-Mylik MA, et al. Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52. J Dermatolog Treat. 2024;35(1):2436607. https:\/\/doi.org\/10.1080\/09546634.2024.2436607.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"789_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jaad.2024.10.104","volume":"92","author":"X Man","year":"2025","unstructured":"Man X, Zaharieva K, Pulka G, \u017bebrowska MA, Deng Y, Mekokishvili L, et al. A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2025;92(4):724\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.104.","journal-title":"J Am Acad Dermatol"},{"key":"789_CR35","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2147\/DDDT.S470619","volume":"18","author":"F Yao","year":"2024","unstructured":"Yao F, Wang C, Ding J, Zhang Q, Zheng L, Zhang Q, et al. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of CMAB015, a candidate Secukinumab biosimilar, with its reference product Cosentyx\u00ae in healthy Chinese male subjects. Drug Des Devel Ther. 2024;18:3891\u2013901. https:\/\/doi.org\/10.2147\/DDDT.S470619.","journal-title":"Drug Des Devel Ther"},{"issue":"10273","key":"789_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Langley RG, Warren RB, Papp KA, Strober B, Paul C, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4.","journal-title":"Lancet"},{"issue":"9","key":"789_CR37","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","volume":"5","author":"K Papp","year":"2023","unstructured":"Papp K, Warren RB, Green L, Reich K, Langley RG, Paul C, et al. Safety and efficacy of Mirikizumab versus Secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study. Lancet Rheumatol. 2023;5(9):e542-52. https:\/\/doi.org\/10.1016\/S2665-9913(23)00120-0.","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"789_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s13555-022-00883-y","volume":"13","author":"A Asahina","year":"2023","unstructured":"Asahina A, Okubo Y, Morita A, Tada Y, Igarashi A, Langley RG, et al. Bimekizumab efficacy and safety in Japanese patients with plaque psoriasis in BE VIVID: a phase 3, ustekinumab and placebo-controlled study. Dermatology Therapy (Heidelb). 2023;13(3):883\u201394. https:\/\/doi.org\/10.1007\/s13555-022-00883-y.","journal-title":"Dermatology Therapy (Heidelb)"},{"issue":"1","key":"789_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjd.17628","volume":"181","author":"K Reich","year":"2019","unstructured":"Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019;181(1):88\u201395. https:\/\/doi.org\/10.1111\/bjd.17628.","journal-title":"Br J Dermatol"},{"key":"789_CR40","doi-asserted-by":"publisher","unstructured":"Reich, K., Gooderham, M., Thaci, D., Crowley, J. J., Langley, R. G., Puig, L., \u2026 Lebwohl,M. (2019). Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial. The Lancet, 394(10198), 576\u2013586. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3.","DOI":"10.1016\/S0140-6736(19)30952-3"},{"issue":"5","key":"789_CR41","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1684\/ejd.2023.4555","volume":"33","author":"TR Kim","year":"2023","unstructured":"Kim TR, Won Y, Kim Y, Won SH, Bae KN, Lee J, et al. Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics. Eur J Dermatol. 2023;33(5):518\u201323. https:\/\/doi.org\/10.1684\/ejd.2023.4555.","journal-title":"Eur J Dermatol"},{"key":"789_CR42","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1038\/s41598-025-94505-0","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang H, Hou S, Kang X, et al. Bmi matters: understanding the link between weight and severe psoriasis. Sci Rep. 2025;15:11158. https:\/\/doi.org\/10.1038\/s41598-025-94505-0.","journal-title":"Sci Rep"},{"issue":"1","key":"789_CR43","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1186\/s12967-025-07130-w","volume":"23","author":"Y Xu","year":"2025","unstructured":"Xu Y, Peng C, Tang S, Zhang Y, Zhen Y, Yin Y, Wang X, Ding Y, Yu Q, Ma R, Shi Y. Association of BMI, BMR, BSA, and body weight with psoriasis severity and treatment response: evidence from a real-world cohort. J Transl Med. 2025;23(1):1129. https:\/\/doi.org\/10.1186\/s12967-025-07130-w. PMID: 41107855; PMCID: PMC12535050.","journal-title":"J Transl Med"},{"key":"789_CR44","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1186\/s12967-025-06723-9","volume":"23","author":"Y Lv","year":"2025","unstructured":"Lv Y, Bian H, Jing Y, et al. IL-17A inhibitors modulate skin microbiome in psoriasis: implications for microbial homeostasis. J Transl Med. 2025;23:817. https:\/\/doi.org\/10.1186\/s12967-025-06723-9.","journal-title":"J Transl Med"},{"issue":"5","key":"789_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054568","volume":"24","author":"YH Huang","year":"2023","unstructured":"Huang YH, Chang LC, Chang YC, Chung WH, Yang SF, Su SC. Compositional alteration of gut microbiota in psoriasis treated with IL-23 and IL-17 inhibitors. Int J Mol Sci. 2023;24(5):4568. https:\/\/doi.org\/10.3390\/ijms24054568.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"789_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/1346-8138.16609","volume":"50","author":"A Morita","year":"2023","unstructured":"Morita A, Tsai T-F, Yee EYW, et al. Efficacy and safety of spesolimab in Asian patients with generalized pustular psoriasis flare: results from the randomized, double-blind, placebo-controlled Effisayil\u2122 1 study. J Dermatol. 2023;50(2):183\u201394. https:\/\/doi.org\/10.1111\/1346-8138.16609.","journal-title":"J Dermatol"},{"key":"789_CR47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12325-021-01899-0","volume":"39","author":"L Cai","year":"2022","unstructured":"Cai L, Li L, Cheng H, et al. Efficacy and safety of HLX03, an adalimumab biosimilar, in patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, phase III study. Adv Ther. 2022;39:583\u201397. https:\/\/doi.org\/10.1007\/s12325-021-01899-0.","journal-title":"Adv Ther"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-025-00789-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00789-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00789-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:06:13Z","timestamp":1772582773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12865-025-00789-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1186\/s12865-025-00789-2","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}